牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, has filed Prospectus Supplement No. 7, amending and supplementing the original prospectus dated June 28, 2023. This supplement includes information from the company's Form 6-Ks filed on December 29, 2023, and February 23, 2024, with the Securities and Exchange Commission. The supplement pertains to the resale of 291,123,200 ordinary shares represented by 727,808 American Depositary Shares. Additionally, Biodexa announced the appointment of Ann Merchant as a non-executive director effective December 31, 2023. Merchant brings extensive experience from her previous roles at MorphoSys AG, Schreiner Medipharm, and Amgen Inc., and currently serves on the board of Alvotech S.A. In research and development updates, Biodexa reported positive top-line Phase I clinical trial results for MTX110 in treating diffuse midline glioma, with a...Show More
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, has filed Prospectus Supplement No. 7, amending and supplementing the original prospectus dated June 28, 2023. This supplement includes information from the company's Form 6-Ks filed on December 29, 2023, and February 23, 2024, with the Securities and Exchange Commission. The supplement pertains to the resale of 291,123,200 ordinary shares represented by 727,808 American Depositary Shares. Additionally, Biodexa announced the appointment of Ann Merchant as a non-executive director effective December 31, 2023. Merchant brings extensive experience from her previous roles at MorphoSys AG, Schreiner Medipharm, and Amgen Inc., and currently serves on the board of Alvotech S.A. In research and development updates, Biodexa reported positive top-line Phase I clinical trial results for MTX110 in treating diffuse midline glioma, with a median overall survival of 16.5 months compared to 10.0 months in a comparable cohort. However, a preclinical experiment to demonstrate tolimidone's potential for beta cell proliferation yielded inconclusive results. Despite this, the company plans to proceed with an in vivo preclinical study and preparations for a Phase IIa study of tolimidone in Type 1 diabetes patients.
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC已提交第7號招股說明書補充文件，對2023年6月28日的原始招股說明書進行了修改和補充。本補充文件包括該公司於2023年12月29日和2024年2月23日向美國證券交易委員會提交的6-K表格中的信息。該補編涉及以727,808股美國存托股爲代表的291,123,200股普通股的轉售。此外，Biodexa宣佈任命安·默特爲非執行董事，自2023年12月31日起生效。Merchant以前在MorphoSys AG、Schreiner Medipharm和Amgen Inc. 任職期間擁有豐富的經驗，目前在Alvotech ...展開全部
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC已提交第7號招股說明書補充文件，對2023年6月28日的原始招股說明書進行了修改和補充。本補充文件包括該公司於2023年12月29日和2024年2月23日向美國證券交易委員會提交的6-K表格中的信息。該補編涉及以727,808股美國存托股爲代表的291,123,200股普通股的轉售。此外，Biodexa宣佈任命安·默特爲非執行董事，自2023年12月31日起生效。Merchant以前在MorphoSys AG、Schreiner Medipharm和Amgen Inc. 任職期間擁有豐富的經驗，目前在Alvotech S.A的董事會任職。在研發最新動態中，Biodexa報告了治療瀰漫性中線神經膠質瘤的 MTX110 一期臨床試驗結果良好，中位總存活率爲16.5個月，而同類群體的總存活率爲10.0個月。但是，一項證明託利米酮具有β細胞增殖潛力的臨床前實驗沒有得出結論性的結果。儘管如此，該公司計劃繼續進行體內臨床前研究，併爲託利米酮在1型糖尿病患者中的IIa期研究做準備。
有用
沒用